Product Description
Mechanisms of Action: Tubulin Binder
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Uruguay
Approved Indications: None
Known Adverse Events: None
Company: CTI BioPharma
Company Location: SEATTLE WA 98121
Company CEO: Adam R. Craig
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer
Phase 2: Non-Small-Cell Lung Cancer|Peritoneal Cancer|Ovarian Cancer|Fallopian Tube Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Esophageal Cancer|Prostate Cancer
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2007-004167-22 | P3 |
Active, not recruiting |
Non-Small-Cell Lung Cancer |
2009-11-23 |
|
| CTI-1071 | P2 |
Completed |
Ovarian Cancer|Peritoneal Cancer|Fallopian Tube Cancer |
2003-02-01 |
|
| PIONEER | P3 |
Terminated |
Non-Small-Cell Lung Cancer|Small Cell Lung Cancer |
None |
|
| NCT00352690 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-06-01 |
|
| CDR0000540438 | P2 |
Terminated |
Prostate Cancer |
2009-07-01 |
|
| D-0433 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2009-11-01 |
|
| CTI#X64001 | P2 |
Completed |
Esophageal Cancer |
2010-02-01 |
|
| CTI-PGT-07-00400 | P3 |
Terminated |
Non-Small-Cell Lung Cancer |
2007-12-25 |
|
| 3C-07-3 | P1 |
Completed |
Colorectal Cancer |
2008-09-01 |
|
| X90003 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2016-12-01 |